AUAUniversity

Support provided by an independent educational grant from Allergan, Astellas and Medtronic

CME Available: https://auau.auanet.org/node/24584

Instructional Course Director(s)

Eric Rovner, MD

Medical University of South Carolina

Instructional Course Faculty(s)

Alan Wein, MD,PHD

Founders Professor and Emeritus Chief of Urology and Director, Residency Program

University of Pennsylvania

Christopher Chapple, MD

Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield Hallam University

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 5th International Consultation on Incontinence," as well as European Association of Urology (EAU) Guidelines, has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy. Currently available agents as well as drugs in development will be discussed.

Learning Objectives:

Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)

Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.

Realize the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies

Analyze the clinical (and theoretical) advantages and limitations of currently available agents

Review potential future pharmacological pathways and therapies for OAB

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/content/integrating-care-oncology-patients-establishing-multidisciplinary-oncology-clinic-advanced

This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting. Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression.

Learning Objectives:

Describe the components of a multidisciplinary urologic cancer cancer and identify the best structure for the practice.

Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients

Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.

Demonstrate an understanding of advances in genomic testing and personalized medicine for urologic cancers.

Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-and-therapeutic-advances-metastatic

Instructional Course Director(s)

Michael Cookson, MD, MMHC

Professor and Chair

University of Oklahoma

Instructional Course Faculty(s)

David Jarrard, MD

University of Wisconsin

Adam Kibel, MD

Brigham Health, Harvard University

William Lowrance, MD

University of Utah, Huntsman Cancer Institute

This course will review the important and newly updated 2018 AUA Guidelines on Castration-Resistant Prostate Cancer. This includes a thorough discussion of new trials and approval of agents for MO non-metastatic nmCRPC. In addition, we will review therapeutic breakthroughs in the management of advanced and metastatic hormone naïve prostate cancer (mHSPPC). Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines. Also, the role of genomic classifiers and genetic testing in the evaluation of CRPC, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA CRPC guidelines in those instances. This course will be a benefit to practicing urologists, oncologists, advanced practice providers, and residents/fellows preparing for their certification exam and physicians preparing for their re-certification exam.

Learning Objectives:

Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC

Understand the sequencing and indications for active treatment with approved agents in the management of nmCRPC

Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines

Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice

Understand and analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/content/chemo...

Instructional Course Director(s)

Costas Lallas, MD

Thomas Jefferson University Hospital

Instructional Course Faculty(s)

Anne Calvaresi, DNP, CRNP

Thomas Jefferson University

Edouard Trabulsi, MD, FACS

Sidney Kimmel Medical College at Thomas Jefferson University

Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects.

Learning Objectives:

Describe the standard of care chemotherapy regimens for genitourinary malignancies

Recall both historic and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates.

Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies.

Recognize and manage the adverse events related to these agents.

Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies.

List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.

Support provided by an independent educational grant from Allergan, Astellas and Medtronic

CME Available: https://auau.auanet.org/node/24581

Instructional Course Director(s)

Kathleen Kobashi, MD, FACS, FPMRS

Virginia Mason Medical Center

Instructional Course Faculty(s)

Sandip Vasavada, MD

Professor of Surgery/Urology

Cleveland Clinic Glickman Urological Institute and Lerner College of Medicine

David Ginsberg, MD

USC Institute of Urology

This course would aim to discuss all guidelines-approved 3rd line therapies for the treatment of overactive bladder (OAB). Case–based discussion will be used adjunctively to illustrate how best to select patients in varying clinical scenarios and how to optimally counsel a patient on each of the available modalities, including onabotulinumtoxinA injection of the bladder, tibial nerve stimulation, and sacral nerve stimulation (SNS). Emerging therapies in neuromodulation will also be introduced.

Optimal patient selection and integration of these therapies into the urology practice will be discussed in detail. Importantly, the technique of onabotulinumtoxinA injection, ideal tibial nerve stimulation, optimal SNS lead placement, and troubleshooting of the failed implant will be highlighted.

Learning Objectives:

Name the available 3rd line therapies for treatment of refractory OAB

Practice the the injection technique for onabotulinumtoxinA for OAB

Employ the technique of tibial nerve stimulation for OAB

Indicate the optimal lead placement for sacroneuromodulation and troubleshooting the failed implant

Identify the upcoming 3rd line therapies for OAB

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/node/24582

Instructional Course Director(s)

Todd Morgan, MD

University of Michigan

Instructional Course Faculty(s)

Leonard Gomella, MD,FACS

Professor And Chair

Thomas Jefferson University

Heather Cheng, MD, PhD

University of Washington

There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g. PARP inhibition), Urologists are suddenly being confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations (present in greater than 10% of men with metastatic disease). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer.

Learning Objectives:

Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening

Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results

Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.

This educational activity is supported by independent educational grants from: Astellas, Merck and Seattle Genetics

CME Available: https://auau.auanet.org/node/24777

In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of advanced and metastatic urothelial carcinoma while discussing key take-home messages from AUA2019 sessions.

Moderator: Kristen R. Scarpato, MD, MPH, Vanderbilt University Medical Center

Faculty:

Anne E. Calvaresi, DNP, CRNP, RNFA, Thomas Jefferson University

Siamak Daneshmand, MD, University of Southern California/Norris Comprehensive Cancer Center

Anthony C. Wong, MD, PhD, University of California, San Francisco

This educational activity is supported by independent educational grants from: Astellas, Merck and Seattle Genetics

CME Available: https://auau.auanet.org/node/24288

In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of non-muscle invasive urothelial carcinoma while discussing key take-home messages from AUA2019 sessions.

Moderator: Kristen R. Scarpato, MD, MPH, Vanderbilt University Medical Center

Faculty:

John L. Gore, MD, MS, FACS, University of Washington

Sima P. Porten, MD, MPH, FACS, University of California, San Francisco

Chad R. Ritch, MD, MBA, University of Miami

The American Urological Association in conjunction with the National Medical Student Education Curriculum Committee is proud to sponsor a free podcast that will provide exposure to the core concepts and terminology underlying the care urologists provide within Transgender Medicine. This webinar will provide an overview of this complex discipline, and is designed to give medical students the ability to engage in thoughtful discourse with colleagues when caring for this patient population. It will also provide specific insight into the ways Urology is emerging as a leading specialty in this discipline, paving the way for optimization of lifelong care, including before and after surgical reconstruction.

Co Host: Ralph W. de Vere White M.D.